Alpha Cognition (ACOG) Restructuring Costs (2023 - 2024)
Alpha Cognition (ACOG) posted quarterly Restructuring Costs of $11779.0 for Q4 2024, down 83.51% year-over-year from $71448.0 in Q1 2024, and up 162.03% quarter-over-quarter from -$18990.0 in Q3 2024.
Alpha Cognition (ACOG) Restructuring Costs (2023 - 2024) Analysis & Trends
Alpha Cognition's Restructuring Costs history runs 2 years deep, the most recent figure standing at $11779.0 for Q4 2024.
- In Q4 2024, Restructuring Costs fell 83.51% year-over-year to $11779.0; the TTM figure through Dec 2024 stood at $66892.0 (changed N/A YoY), while the FY2024 annual figure was $16160.0, down 78.69% from the prior year.
- Restructuring Costs for Q4 2024 stood at $11779.0, up from -$18990.0 in the prior quarter.
- The five-year high for Restructuring Costs was $71448.0 in Q4 2023, with the low at -$18990.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Alpha Cognition | 209.03 Mn | 167.59 Mn | 5.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 11,779.00 |
| Sep 30, 2024 | -18,990.00 |
| Dec 31, 2023 | 71,448.00 |
| Sep 30, 2023 | 2,655.00 |